semaglutide for obesity patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral at a dose of 50 mg Semaglutide as a GLP-1 Agonist:

Once you stop taking semaglutide, you should be able to maintain your results through healthy choices

You and your provider should receive a notice explaining the decision

This case highlights an important reminder: while AI tools can be useful, they should never replace professional medical advice

Glucagon receptor agonism directly promotes hepatic fat clearance, making mazdutide mechanistically suited for MASH/NASH-related metabolic goals beyond weight loss alone

My hope is that by explaining, and potentially convincing you of, their inevitability and the health inequity that will arise from delaying coverage, the conversation shifts away from should these be covered? to how do we ensure everyone who needs them is covered as soon as possible? How do we, collectively, best fight for patient access to these new revolutionary treatments

GLP-1 RAs and naltrexone/bupropion have shown efficacy in attenuating hedonic drive through hypothalamic and mesolimbic modulation, offering therapeutic tools beyond caloric restriction [200]